Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC)

被引:2
|
作者
Pothuri, Vikram [1 ]
Rodriguez, Jorge G. Zarate [1 ]
Kasting, Christina [1 ]
Leigh, Natasha [1 ,2 ]
Hawkins, William G. [1 ,2 ]
Sanford, Dominic E. [1 ,2 ]
Fields, Ryan C. [1 ,2 ,3 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Alvin J Siteman Comprehens Canc Ctr, Sch Med, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave Campus Box 8109, St Louis, MO 63110 USA
关键词
RACIAL DISPARITIES; CANCER;
D O I
10.1016/j.hpb.2023.08.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The impact of neighborhood deprivation on outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) is not well-described and represents an area to improve disparities.Methods: We retrospectively queried our prospectively maintained database of patients with PDAC (2014-2022). Patients were grouped by Area Deprivation Index (ADI) and rural-urban commuting area (RUCA) codes. Cox proportional hazards models and logistic regressions were used to investigate effect on overall survival (OS) and adjuvant therapy administration.Results: 536 patients were included. High ADI patients (more disadvantaged, n = 184) were more likely to identify as non-Hispanic Black (17.9% vs. 4.8%, p < 0.01) and were more likely to be from rural areas (49.5% vs. 18.5%, p < 0.01). High ADI was independently associated with decreased OS (HR (95% CI): 1.31 (1.01-1.69), p = 0.04). Urban high ADI patients were 3.5 times more likely to receive adjuvant therapy than rural high ADI patients (OR [95% CI]: 3.48 [1.26-9.61], p = 0.02).Conclusion: Patients from the most disadvantaged neighborhoods have decreased OS. Access to adjuvant therapy likely contributes to this disparity in rural areas. Investigation into sources of this OS disparity and identification of barriers to adjuvant therapy will be crucial to improve outcomes in un-derserved patients with PDAC.
引用
收藏
页码:1545 / 1554
页数:10
相关论文
共 50 条
  • [41] Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma
    Mori, Shozo
    Aoki, Taku
    Sakuraoka, Yuhki
    Shimizu, Takayuki
    Yamaguchi, Takamune
    Park, Kyung-Hwa
    Matsumoto, Takatsugu
    Shiraki, Takayuki
    Iso, Yukihiro
    Kubota, Keiichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (01) : 109 - 120
  • [42] Development and Validation of a MicroRNA Signature Predictive of Local-Regional Recurrence and Overall Survival after Resection of Pancreatic Ductal Adenocarcinoma (PDAC)
    Sebastian, N.
    Webb, A.
    Merrell, K. W.
    Koay, E. J.
    Zhang, L.
    Wilhite, T. J.
    Elganainy, D.
    Robb, R.
    Wald, P. M.
    Walston, S. A., Jr.
    Miller, E. D.
    Pardo, D. A. Diaz
    Cloyd, J.
    Manilchuk, A.
    Dillhoff, M.
    Williams, T. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S208 - S209
  • [43] Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma
    Shozo Mori
    Taku Aoki
    Yuhki Sakuraoka
    Takayuki Shimizu
    Takamune Yamaguchi
    Kyung-Hwa Park
    Takatsugu Matsumoto
    Takayuki Shiraki
    Yukihiro Iso
    Keiichi Kubota
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 109 - 120
  • [44] Perioperative risk factors for overall survival of patients with pancreatic ductal adenocarcinoma underwent laparoscopic pancreaticoduodenectomy
    Zhang, Jing
    Cai, He
    Zhang, Man
    Cai, Yunqiang
    Peng, Bing
    UPDATES IN SURGERY, 2025,
  • [45] Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma
    Fei Qinglin
    Pan Yu
    Yu Xingxing
    Lin Ronggui
    Lin Xianchao
    Huang Heguang
    胰腺病学杂志(英文), 2020, 03 (03) : 147 - 153
  • [46] CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients
    Sun, Yukun
    Wu, Guangdong
    Cheng, Kok Suen
    Chen, Anqi
    Neoh, Kuang Hong
    Chen, Shuiyu
    Tang, Zhewen
    Lee, Poh Foong
    Dai, Menghua
    Han, Ray P. S.
    EBIOMEDICINE, 2019, 46 : 133 - 149
  • [47] Correlation of FDG and FPSG PET parameters with sarcopenia and overall survival in patients with pancreatic ductal adenocarcinoma
    Cheng, Mei-Fang
    Tien, Yu-Wen
    Chuang, Pei-Ju
    Hsin, Ling-Wei
    Ko, Kuan-Yin
    Liao, Wei-Chih
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [48] Survival benefits and disparities in radiation therapy for elderly patients with pancreatic ductal adenocarcinoma
    Bi-Yang Cao
    Qian-Qian Wang
    Le-Tian Zhang
    Chen-Chen Wu
    Fang Tong
    Wei Yang
    Jing Wang
    World Journal of Gastrointestinal Oncology, 2023, 15 (01) : 155 - 170
  • [49] Use of Beta Blockers Has No Impact on Survival of Patients With Pancreatic Ductal Adenocarcinoma
    Yang, A.
    Lucas, A. L.
    PANCREAS, 2017, 46 (10) : 1445 - 1445
  • [50] Survival benefits and disparities in radiation therapy for elderly patients with pancreatic ductal adenocarcinoma
    Cao, Bi-Yang
    Wang, Qian-Qian
    Zhang, Le-Tian
    Wu, Chen-Chen
    Tong, Fang
    Yang, Wei
    Wang, Jing
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (01) : 155 - 170